<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-165824</identifier>
<setSpec>1131-3587</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Clinical development of edoxaban. Phase-II studies</dc:title>
<dc:description xml:lang="en">Edoxaban is a direct inhibitor of factor Xa that has been evaluated for the prevention of cerebral and systemic thromboembolic events in patients with nonvalvular atrial fibrillation. A comprehensive program of phase-II studies has demonstrated that administration of a dose of 30 or 60 mg once a day rather than twice daily is associated with fewer hemorrhagic events than warfarin. The dose should be lower in certain conditions (e.g. patients with moderate renal impairment or a body weight &amp;#8804;60 kg and those taking P-glycoprotein inhibitors) in order to reduce the risk of hemorrhagic complications (AU)</dc:description>
<dc:creator>Almendro-Delia, Manuel</dc:creator>
<dc:creator>Hidalgo-Urbano, Rafael</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El edoxabán es un inhibidor directo del factor Xa que se ha evaluado para la prevención de eventos tromboembólicos cerebrales y sistémicos en pacientes con fibrilación auricular no valvular. Un amplio programa de estudios en fase II ha demostrado que las dosis de 30 y 60 mg administradas una vez al día frente a 2 veces al día se asocian a menos eventos hemorrágicos en comparación con warfarina. Es necesario ajustar las dosis en casos seleccionados (insuficiencia renal moderada, toma de inhibidores de la glucoproteína P y peso &amp;#8804; 60 kg) para reducir la tasa de complicaciones hemorrágicas (AU)</dc:description>
<dc:source>Rev. esp. cardiol. Supl. (Ed. impresa);16(supl.A): 67a-69a, 2016. graf</dc:source>
<dc:identifier>ibc-165824</dc:identifier>
<dc:title xml:lang="es">Desarrollo clínico del edoxabán. Estudios en fase II</dc:title>
<dc:subject>^d30963</dc:subject>
<dc:subject>^d1287^s22057</dc:subject>
<dc:subject>^d14308^s22054</dc:subject>
<dc:subject>^d15261^s22079</dc:subject>
<dc:subject>^d651^s22079</dc:subject>
<dc:subject>^d55662^s22079</dc:subject>
<dc:subject>^d34262^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d34247^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>201600</dc:date>
</metadata>
</record>
</ibecs-document>
